From Access to Adherence: The Challenges of Antiretroviral Treatment - Studies from Botswana, Tanzania and Uganda, 2006: Factors that facilitate or constrain adherence to antiretroviral therapy among adults in Uganda: a pre-intervention study: References

From Access to Adherence: The Challenges of Antiretroviral Treatment - Studies from Botswana, Tanzania and Uganda, 2006
(2006; 320 pages)

Índice de contenido

Acknowledgments
Acronyms and abbreviations
Foreword
1. On hunger, transport costs and waiting time: a synthesis of challenges to ARV adherence in three African countries
	Introduction
	Methods
	Discussion
	Conclusion
	References
2. Overview of antiretroviral therapy, adherence and drug-resistance
	Background
	References
3. From training to action: the process of engaging health professionals in operational research on adherence to antiretroviral therapy
	Introduction
	Promoting the rational use of drugs
	Promoting Rational Drug Use in the Community course
	Three ARV adherence studies: the process
	How the process was funded
	Discussion and conclusion
	References
	Annex 1: PRDUC course participants by region, type of institution, sex and source of funding
	Annex 2: URLs for country proposals
	Annex 3: Call for proposals
4. There's hope - early observations of ARV treatment roll-out in South Africa
Factors that facilitate or constrain adherence to antiretroviral therapy among adults at four public health facilities in Botswana: a pre-intervention study
	Acknowledgements
	Acronyms and abbreviations
	Executive summary
	Chapter 1: Introduction
		1.1 Research problem
		1.2 Research questions
		1.3 Study objectives
	Chapter 2: Background
		2.1 History of HIV and AIDS in Botswana
		2.2 Botswana's ART programme
		2.3 Literature review
		2.4 Definition of concepts
	Chapter 3: Methodology
		3.1 Introduction
		3.2 Study design
		3.3 Study population
		3.4 Description of study sites
		3.5 Inclusion and exclusion criteria
		3.6 Selection and training of data collectors
		3.7 Qualitative data collection
		3.8 Observations
		3.9 Semi-structured interviews
		3.10 Exit interviews
		3.11 Focus group discussions
		3.12 Quantitative data
		3.13 Data analysis
		3.14 Emic perspective
		3.15 Ethical considerations
		3.16 Feedback
	Chapter 4: Quantitative results
		4.1 Adherence measurement tool results
		4.2 Rates of adherence to ARVs
		4.3 Reasons for skipping medication
		4.4 Factors affecting adherence to ART
		4.5 Predictors of adherence to ART
		4.6 Quantitative results of exit interviews
	Chapter 5: Qualitative results
		5.1 Constraints to adherence to ART
		5.2 Facilitators of adherence to ART
		5.3 Observation of health facilities 5.3.1 Structural issues
		5.4 National level policy issues
	Chapter 6: Discussion, conclusion and recommendations
		6.1 Discussion
		6.2 Conclusions
		6.3 Recommendations
	References
	Annex 1: Mean of rates adherence
	Annex 2: Multivariate logistic regression analyses on the predictor variables
	Annex 3: Questionnaires
A study on antiretroviral adherence in Tanzania: a pre-intervention perspective, 2005
	Acknowledgements
	Acronyms and abbreviations
	Executive summary
	Chapter 1: Introduction
		1.1 Background
		1.2 Rationale
		1.3 Literature review
		1.4 Problem statement
		1.5 Objectives
		1.6 Output
	Chapter 2: Methodology
		2.1 Study design
		2.2 Study population
		2.3 Inclusion and exclusion criteria for interviewees
		2.4 Quantitative data
		2.5 Qualitative data
		2.6 Data collection tools
		2.7 Pilot study
		2.8 Sample size and sampling strategy
		2.9 Data collection
		2.10 Ethics
	Chapter 3: Study areas
		3.1 Health care facilities
	Chapter 4: Quantitative results
		4.1 Demographic characteristics of ARV users
		4.2 Adherence rates
	Chapter 5: Qualitative results
		5.1 Factors that influence adherence to ARVs from the users' perspective
		5.2 Quality of operating structures
		5.3 Opinions and suggestions given by respondents to improve provision of ARVs
	Chapter 6: Discussion, conclusion and recommendations
		6.1 Discussion
		6.2 Conclusion
		6.3 Recommendations
		6.4 Proposed interventions
	References
	Annex 1: Exit interview with ARV users
	Annex 2: Semi-structured interview with ARV users
	Annex 3: ARV users, FGDs
	Annex 4: Adherence measurement tools
	Annex 5: Key informant interview
	Annex 6: Semi-structured interviews (with staff)
	Annex 7: Observation (consultations)
	Annex 8: Observation of antiretroviral
Factors that facilitate or constrain adherence to antiretroviral therapy among adults in Uganda: a pre-intervention study
	Acknowledgements
	Glossary
	Executive summary
	Chapter 1: Introduction
		1.1 Background
		1.2 Research problem
		1.3 Research objective
	Chapter 2: Background to the study
		2.1 History of AIDS in Uganda
		2.2 History of ARVs in Uganda
	Chapter 3: Literature review
		3.1 Importance of adherence to ART
		3.2 Measurement of adherence
		3.3 Factors affecting adherence to ART
		3.4 Impact of the drug regimen on adherence
		3.5 Treatment characteristics affecting adherence 3.5.1 Physical state and disease stage
		3.6 The clinic setting and service provision
		3.7 Simplifying treatment regimes to improve adherence
		3.8 Conceptual framework
	Chapter 4: Methodology
		4.1 Study design
		4.2 Study population
		4.3 Inclusion and exclusion criteria
		4.4 Sample size and selection
		4.5 Data collector selection and training
		4.6 Pilot testing
		4.7 Data collection
		4.8 Data analysis
		4.9 Evaluation of methods
		4.10 Ethical considerations
	Chapter 5: Description of the study sites
		5.1 Jinja Regional Referral Hospital
		5.2 Nile Treatment Centre
		5.3 Study limitations
	Chapter 6: Results
		6.1 Demographic characteristics of ARV users
		6.2 Factors influencing adherence to ART
	Chapter 7: Discussion, conclusions and recommendations
		7.1 Discussion
		7.2 Conclusions
		7.3 Recommendations
	References
Back cover

References

1. Arnsten JH et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV- infected drug users: comparison of self-report and electronic monitoring. Clinical Infectious Diseases, Oct 15;33(8):1417-23.

2. Bachiller P et al. (1998). Drug compliance in patients starting saquinavir. 12th World AIDS Conference, Geneva, Switzerland. Abstract no. 32392.

3. Buhrich N, Judd FK. HIV and psychiatric disorders. In: G. Stewart ed. Managing HIV. Sydney: Australasian Medical Publishing Company, 1997.

4. Burgos M et al. (1998). Obstacles in treatment adherence: patient reasons. 12th World AIDS Conference, Geneva, Switzerland. Abstract no. 32400.

5. Byakika-Tusiime J et al. (2003). Ability to purchase and secure stable therapy are significant predictors of non-adherence to antiretroviral therapy in Kampala Uganda [abstract]. Tenth Conference on Retro viruses and Opportunistic Infections, Boston, USA, February 2003.

6. Carter M (2005). Adherence. Information series for HIV-positive people. NAM. Available at: http://www.aidmap.com

7. Catz S, Heckman T, Kochman A (1999). Adherence to HAART therapy among older adults living with HIV disease. Fourth International Conference on the Biophysical Aspects of HIV Infection, Ottowa, Canada.Poster 18.

8. Dansburg D et al. (2003). Pill burden predicts adherence, regimen discontinuation or switch, viral load and CD4 cell response in nationwide US sample of HIV+ ARV naïve people on PI therapy. Antiviral Therapy 8:395.

9. Erlon JA, Mellors P (1999). Adherence to combination therapy in persons living with HIV: balancing the hardships and the blessings. Journal of the Association of Nurses in AIDS Care, 10(4):75-84.

10. Farmer KC (1999). Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics, 21(6):1999.

11. Furtado MR et al. (1999). Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent HAART therapy. New England Journal of Medicine, 340(21): 1614-1622.

12. Gill CJ et al. (2005). No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS, 19(12):1243-1249.

13. Green EC. Rethinking AIDS prevention. Learning from success in developing countries. Westport, USA, Praeger, 2003.

14. Grierson J et al. HIV futures II: the health and well being of people with HIV/AIDS in Australia. Monograph Series No. 17, Melbourne, La Trobe University, 2000.

15. Hirschhorn L et al. (1998). Highly active HAART therapy in the "real world": experiences in an inner-city community health center. 12th World AIDS Conference, Geneva, Switzerland. Abstract 32334.

16. Jones JL, Nakashima AK, Kaplan JE (1999). Adherence to primary prophylaxis for pneumocystis carinii pneumonia: results from a multi-state interview project. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA. Abstract no. 586.

17. Kaplin A et al. (1999). Adherence to protease inhibitor therapy and viral load. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA. Abstract no. 96.

18. Katabira ET (2002). The promise and challenges of antiretroviral therapy in developing countries. Paper presented at the 9^th Conference on Retroviruses and Opportunistic Infection. Symposium session 30.

19. Kirkland LR et al. (2002). Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clinical Infectious Diseases, 34: 511-8.

20. Kityo et al. (2002). A trial of regimens to suppress HIV/AIDS in Ugandan adults. Paper presented at the 13^th International Conference on HIV/AIDS, Barcelona, Spain, July 2002.

21. Meisler A et al. (1993). Adherence to clinical trials among women, minorities and injecting drug users. Paper presented at the 9th International Conference on AIDS, Berlin, Germany.

22. Ministry of Health. National strategic framework for expansion of HIV/AIDS care and support 2001/2-2006/7. Kampala, Ministry of Health of Uganda, 2001.

23. Ministry of Health. National HIV/AIDS Sero-Survey 2005. Kampala, Ministry of Health of Uganda, 2005.

24. Motashari F et al. (1998). Acceptance and adherence with HAART therapy among HIV- infected women in a correctional facility. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18:341-348.

25. Mugyenyi P. No second best in AIDS care. In: American Foundation for AIDS Research HIV/AIDS treatment directory. American Foundation for AIDS Research, New York, 2001.

26. Mugyenyi P (2002). HIV/AIDS situation in Africa. Statement by P. Mugyenyi, Director, Joint Clinical Research Centre, Kampala, Uganda.

27. Nemecheck P, Tritle D (1998). A survey evaluating pharmacy-related resources and their relation to drug adherence. 12th World AIDS Conference, Geneva, Switzerland. Abstract no. 98.

28. Pallela FJ et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338 (13):853-860.

29. Paterson DL, Swindells S, Mohr J (1999). How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA. Abstract no. 92.

30. Paterson DL et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine,133(l):21-30.

31. Uganda AIDS Commission. Twenty years of HIV/AIDS in the world: evolution of the epidemic and response in Uganda. Kampala, Uganda AIDS Commission, 2001. Available at: http://www.aidsuganda.org/pdf/20 yrs of hiv.pdf

32. UN Integrated Regional Information Networks. Uganda: AIDS treatment capacity overwhelmed, says NGO Official. October 17, 2005.

33. UNAIDS/WHO. AIDS epidemic update: Geneva, Joint United Nations Programme on AIDS and World Health Organization, 2005.

34. UNAIDS (2005). Progress made in the implementation of the Declaration of Commitment on HIV/AIDS. Report of the Secretary-General. New York, United Nations, 2 June 2005.

35. Vitolins MZ et al. (2000). Measuring adherence to behavioral and medical interventions. Controlled Clinical Trials 21:188S-194S.

36. Weiser S et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34(1): 281-288.

37. Wenger N et al. (1999). Patient characteristics and attitudes associated with HAART adherence. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA. Abstract no. 981.

38. Williams A, Friedland G (1997). Adherence, compliance, and HAART. AIDS Clinical Care, 9(7):51-53.